Yifah Yaron

Yifah Yaron

Company: Harpoon Therapeutics

Job title: Executive Medical Director


Spotlight on HPN424; a Novel, Half-life extended, PSMA/ CD3 specific TriTAC for the Treatment of Metastatic Prostate Cancer 3:45 pm

• Understand HPN424; a small (~50kD), single-chain, globular protein of three antibody fragment-based domains that target PSMA, CD3 and albumin • Examine how “TriTAC” (Tri-specific T Cell Activating Construct) design has been optimized to recruit T cells at low target density, penetrate solid tumors more efficiently, and has extended serum half-life • Take a look…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.